Aptevo Therapeutics Inc (APVO) — Cash Flow-to-Debt Ratio
Aptevo Therapeutics Inc (APVO) has a Cash Flow-to-Debt Ratio of -0.96x as of March 2026, meaning its operating cash flow of $-7.96 Million could theoretically repay -1% of its total liabilities ($8.29 Million) in one year. See APVO free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aptevo Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Aptevo Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Aptevo Therapeutics Inc.
Annual Cash Flow-to-Debt Ratio for Aptevo Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Aptevo Therapeutics Inc. Check APVO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.61x | $-25.59 Million | $9.81 Million | ▼ -18.8% |
| 2024 | -2.19x | $-23.79 Million | $10.84 Million | ▼ -136.2% |
| 2023 | -0.93x | $-11.73 Million | $12.62 Million | ▲ +28.2% |
| 2022 | -1.29x | $-21.02 Million | $16.24 Million | ▼ -230.7% |
| 2021 | -0.39x | $-21.68 Million | $55.38 Million | ▲ +50.7% |
| 2020 | -0.79x | $-29.32 Million | $36.95 Million | ▲ +22.2% |
| 2019 | -1.02x | $-42.38 Million | $41.57 Million | ▲ +26.5% |
| 2018 | -1.39x | $-51.42 Million | $37.09 Million | ▼ -16.6% |
| 2017 | -1.19x | $-41.57 Million | $34.97 Million | ▼ -33.2% |
| 2016 | -0.89x | $-36.86 Million | $41.29 Million | ▲ +56.4% |
| 2015 | -2.05x | $-48.76 Million | $23.84 Million | ▼ -10.4% |
| 2014 | -1.85x | $-47.01 Million | $25.36 Million | — |